Clinical trial

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

NCT04178460

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-02-03

PhasePHASE1

Study timeline

Study start (actual)2020-02-03Date precision: day

Registry last updated2022-06-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Gastric Cancerunresolved

Triple Negative Breast Cancerunresolved

Biliary Tract Carcinomaunresolved

Endometrial Carcinomaunresolved

Interventions

Niraparib combined with MGD013DRUG

Sponsors & collaborators

Zai Lab (Shanghai) Co., Ltd.lead sponsor

Mapped research locations

ZhengzhouHenan, China2 BeijingBeijing Municipality, China1 ShanghaiShanghai Municipality, China1 GuangzhouGuangdong, China1 BeijingChina1 HangzhouZhejiang, China1 WuhanHubei, China1 ChengduSichuan, China1 GuangzhouChina1 TianjinTianjin Municipality, China1 ShenyangLiaoning, China1 WuhanChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04178460 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.